<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147650</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VOS-2019-01</org_study_id>
    <nct_id>NCT04147650</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome</brief_title>
  <acronym>AUDREY</acronym>
  <official_title>A Randomized, Double-Masked, Vehicle-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution (VOS) in Subjects With Dry Eye Syndrome (DES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled,
      Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%,
      0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2/3, multi-center, randomized, double-masked, vehicle-controlled study to
      assess the efficacy and safety of three different concentrations of VOS when administered in
      both eyes (OU) twice a day (BID) over 12 weeks in subjects with mild to moderate DES.
      Subjects will undergo a 14- to 17-day run-in period in which VOS vehicle will be
      self-administered OU, BID. Subjects will be re-assessed to confirm they meet all of the
      inclusion criteria and none of the exclusion criteria. It is estimated that the study will
      enroll approximately 480 subjects across approximately 9 study centers. Eligible subjects
      will be randomized in a 1:1:1:1 ratio to one of the following study treatment groups after
      the 14- to 17-day run-in period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to one of the following treatment groups:
Investigational product (IP): one drop 0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks, one drop 0.10% VOS OU BID over 12 weeks, or one drop 0.20% VOS OU BID over 12 weeks.
Comparator: one drop VOS vehicle OU BID over 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a ≥10 mm increase from baseline in Schirmer Tear Test (STT)</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Proportion of subjects with a ≥10 mm increase from baseline in STT at Week 4 in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eye Dryness</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Mean change from baseline in Eye Dryness Visual Analogue Scale (VAS) in subjects with a baseline Eye Dryness VAS score ≥60mm. Eye Dryness Visual Analogue Scale (0%-100%). 0% corresponds to &quot;no discomfort&quot; and 100% corresponds to &quot;maximal discomfort.&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>0.05% Voclosporin Ophthalmic Solution (VOS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.10% VOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.20% VOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.05% Voclosporin Ophthalmic Solution (VOS)</intervention_name>
    <description>0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
    <arm_group_label>0.05% Voclosporin Ophthalmic Solution (VOS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.10% VOS</intervention_name>
    <description>0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
    <arm_group_label>0.10% VOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.20% VOS</intervention_name>
    <description>0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks</description>
    <arm_group_label>0.20% VOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution</intervention_name>
    <description>Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks</description>
    <arm_group_label>Vehicle Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age.

          -  Have a documented history of Dry Eye prior to Visit 1.

          -  Willing and able to follow protocol procedures and instructions.

        Exclusion criteria:

          -  Have undergone cataract or LASIK surgery within 1 year prior to Visit 1.

          -  Recent or current evidence of infection or inflammation in either eye.

          -  Current evidence of blepharitis, other meibomian gland dysfunction, conjunctivitis or
             history of herpes simplex or zoster keratitis in either eye.

          -  Have used any investigational drug or device within 30 days prior to Visit 1.

          -  Have used ophthalmic drugs (any topical eye medications) including prescription
             medication and over the counter (OTC) agents on the date of Visit 1.

          -  Have worn contact lenses 24 hours prior to Visit 1.

          -  Have used Xiidra® (lifitegrast) within 14 days prior to Visit 1.

          -  Have used Calcineurin Inhibitors (CNIs) such as Restasis® (cyclosporin ophthalmic
             emulsion) or CequaTM within 30 days prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernanda Rospide</last_name>
    <phone>250-744-2487</phone>
    <email>frospide@auriniapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Palmen</last_name>
    <email>mpalmen@auriniapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Raynham</city>
        <state>Massachusetts</state>
        <zip>02767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurinia Investigative Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Calcineurin Inhibitors</keyword>
  <keyword>Dry Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

